Gain Therapeutics Inc (GANX) - Total Assets
Based on the latest financial reports, Gain Therapeutics Inc (GANX) holds total assets worth $18.74 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net asset quality index of Gain Therapeutics Inc to measure how much of total assets are equity-financed.
Gain Therapeutics Inc - Total Assets Trend (2018–2025)
This chart illustrates how Gain Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Explore how much of Gain Therapeutics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Gain Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Gain Therapeutics Inc's total assets of $18.74 Million consist of 97.5% current assets and 2.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 91.3% |
| Accounts Receivable | $802.69K | 3.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $102.84K | 0.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Gain Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Gain Therapeutics Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gain Therapeutics Inc's current assets represent 97.5% of total assets in 2025, an increase from 60.9% in 2018.
- Cash Position: Cash and equivalents constituted 91.3% of total assets in 2025, up from 49.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 3.5% of total assets.
Gain Therapeutics Inc Competitors by Total Assets
Key competitors of Gain Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Gain Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.69 | 2.22 | 18.08 |
| Quick Ratio | 4.69 | 2.22 | 18.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.34 Million | $6.12 Million | $41.85 Million |
Gain Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Gain Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.19 |
| Latest Market Cap to Assets Ratio | 3.33 |
| Asset Growth Rate (YoY) | 88.2% |
| Total Assets | $22.82 Million |
| Market Capitalization | $75.92 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Gain Therapeutics Inc's assets at a significant premium (3.33x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Gain Therapeutics Inc's assets grew by 88.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Gain Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Gain Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $22.82 Million | +88.22% |
| 2024-12-31 | $12.12 Million | -34.85% |
| 2023-12-31 | $18.61 Million | -22.78% |
| 2022-12-31 | $24.10 Million | -38.18% |
| 2021-12-31 | $38.99 Million | +305.91% |
| 2020-12-31 | $9.60 Million | +1354.58% |
| 2019-12-31 | $660.29K | -18.65% |
| 2018-12-31 | $811.63K | -- |
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and t… Read more